180 related articles for article (PubMed ID: 30962345)
1. Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community.
Potron A; Hocquet D; Triponney P; Plésiat P; Bertrand X; Valot B
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962345
[TBL] [Abstract][Full Text] [Related]
2. OXA-48-like carbapenemases in
Sattler J; Noster J; Stelzer Y; Spille M; Schäfer S; Xanthopoulou K; Sommer J; Jantsch J; Peter S; Göttig S; Gatermann SG; Hamprecht A
Emerg Microbes Infect; 2024 Dec; 13(1):2353310. PubMed ID: 38712879
[TBL] [Abstract][Full Text] [Related]
3. Increased Resistance to Carbapenems in
Bontron S; Poirel L; Kieffer N; Savov E; Trifonova A; Todorova I; Kueffer G; Nordmann P
Microb Drug Resist; 2019 Jun; 25(5):663-667. PubMed ID: 30676261
[No Abstract] [Full Text] [Related]
4. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
[No Abstract] [Full Text] [Related]
5. Molecular epidemiology of CTX-M-type extended-spectrum β-lactamase-producing Proteus mirabilis isolates in Taiwan.
Huang CW; Chien JH; Peng RY; Tsai DJ; Li MH; Lee HM; Lin CF; Lee MC; Liao CT
Int J Antimicrob Agents; 2015 Jan; 45(1):84-5. PubMed ID: 25446905
[No Abstract] [Full Text] [Related]
6. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
7. First report of bla
Leulmi Z; Kandouli C; Mihoubi I; Benlabed K; Lezzar A; Rolain JM
J Glob Antimicrob Resist; 2019 Mar; 16():125-129. PubMed ID: 30217548
[TBL] [Abstract][Full Text] [Related]
8. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal Amplification of the blaOXA-58 Carbapenemase Gene in a Proteus mirabilis Clinical Isolate.
Girlich D; Bonnin RA; Bogaerts P; De Laveleye M; Huang DT; Dortet L; Glaser P; Glupczynski Y; Naas T
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855079
[TBL] [Abstract][Full Text] [Related]
10. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L
Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of Multidrug-Resistant Proteus mirabilis Clones Carrying a Novel Integron-Borne
Ramos AC; Cayô R; Carvalhaes CG; Jové T; da Silva GP; Sancho FMP; Chagas-Neto T; Medeiros EAS; Gales AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158274
[TBL] [Abstract][Full Text] [Related]
12. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis.
Bonnet R; Marchandin H; Chanal C; Sirot D; Labia R; De Champs C; Jumas-Bilak E; Sirot J
Antimicrob Agents Chemother; 2002 Jun; 46(6):2004-6. PubMed ID: 12019126
[TBL] [Abstract][Full Text] [Related]
13. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [
